For customers outside of Japan
We established our Indian operations in 2010. The country boasts one of the largest concentrations of biotech companies in the world. The government wants to expand on this, aiming to increase the number of companies from the present 500 to 2,000 by 2020 by investing US$146.7 million. The government has also been collaborating with Australia on clinical research via the Indo-Australian Boosting Gold Fellowship. By the end of 2017, the biotech market is expected to grow to US$11.6 billion.
Health Expenditure per Capita
(2018, US$)
$65
Source: Financing Global Health Database 2018
Population(2019)
1366
million people
Source: The World Bank
Burden of Disease DALYs Causes % of Total DALYs
(2017, all ages/both sexes)
Neonatal disorders (9.25%)
Ischemic heart disease (7.71%)
Chronic obstractive pulmonary
disease (5.15%)
Source: Institute Health Matrics and Evaluation GBD
NDA Approval Time
12
months
18
months
India's regulatory reforms for clinical trials
Due to low costs and a large patient population, India was previously considered a top-tier location for clinical trials. However, India’s limited infrastructure and less-efficient regulations have resulted in many ...
The role of the Clinical Trials Registry – India (CTRI)
The Clinical Trials Registry - India (CTRI) is hosted at the National Institute of Medical Statistics in the Indian Council of Medical Research. Launched in July 2007, the CTRI is a FREE online portal for the recording and publishing ...
Contact Us
Monitoring
Share this page